Investigational antiviral drugs for the treatment of COVID-19

被引：0
|
作者：
Vegivinti, C. T. R. [1 ]
Assi, M. [2 ]
Talwani, R. [3 ]
Koblizek, V [4 ,5 ]
Burke, K. [6 ]
Temesgen, Z. [7 ]
机构：
[1] Manipal Acad Higher Educ MAHE, Kasturba Med Coll, Dept Gen Med, Manipal, Karnataka, India
[2] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA
[3] Univ Maryland, Div Infect Dis, Baltimore, MD 21201 USA
[4] Charles Univ Prague, Univ Hosp Hradec Kralove, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med, Prague, Czech Republic
[6] Wolters Kluwer, Clin Effectiveness, Indianapolis, IN USA
[7] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN USA
来源：
DRUGS OF THE FUTURE | 2021年 / 46卷 / 09期
基金：
美国国家卫生研究院;
关键词：
COVID-19; SARS-CoV-2; Remdesivir; Hydroxychloroquine; Lopinavir/ritonavir; Ribavirin; Ivermectin; Favipiravir; Umifenovir; Camostat; Nafamostat Nitazoxanide; DAS-181; RESPIRATORY SYNDROME CORONAVIRUS; SIALIDASE FUSION PROTEIN; NAFAMOSTAT MESILATE; INTERFERON-THERAPY; RIBAVIRIN; INHIBITOR; DAS181; IVERMECTIN; RITONAVIR; INFECTION;
D O I：
10.1358/dof.2021.46.9.3293585
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov , which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.
引用
收藏
页码：697 / 710
页数：14
相关论文
共 50 条
  • [31] Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
    Punekar, Madhura
    Kshirsagar, Manas
    Tellapragada, Chaitanya
    Patil, Kanchankumar
    MICROBIAL PATHOGENESIS, 2022, 168
  • [32] Investigational Antivirals for Managing COVID-19
    Panesar, Kiran
    US PHARMACIST, 2021, 46 (02) : 29 - 35
  • [33] Investigational immunomodulatory therapies for COVID-19
    Assi, M.
    Koshy, K. M.
    El Atrouni, W.
    Burke, K.
    Berg, M.
    Opardija, A.
    Temesgen, Z.
    DRUGS OF THE FUTURE, 2021, 46 (09) : 711 - 729
  • [34] Identification of FDA Approved Antiviral Drugs for COVID-19 Treatment using Unbiased Virtual Screening
    Greer, Rory
    Song, Yuwei
    Patton, Michael J.
    Might, Matthew
    Harrod, Kevin
    Petit, Chad M.
    Song, Yuhua
    BIOPHYSICAL JOURNAL, 2021, 120 (03) : 204A - 204A
  • [35] Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy
    Seki, Masafumi
    Hashimoto, Kosuke
    Kondo, Nami
    Ohya, Yoshitaka
    Kotajima, Futoshi
    Mitsutake, Kotaro
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 7117 - 7124
  • [36] Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment
    Wang, Yan
    Chen, Lei
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 889
  • [37] Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19
    AlAjmi, Mohamed F.
    Azhar, Asim
    Owais, Mohd
    Rashid, Summya
    Hasan, Sadaf
    Hussain, Afzal
    Rehman, Md Tabish
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (17): : 6676 - 6688
  • [38] Strategies to Promote Equity in COVID-19 Antiviral Treatment
    Fiscella, Kevin
    Sanders, Mechelle
    Yaeger, Jeffrey
    JAMA HEALTH FORUM, 2022, 3 (03):
  • [39] Antiviral agents for the treatment of COVID-19: Progress and challenges
    Singh, Manmeet
    de Wit, Emmie
    CELL REPORTS MEDICINE, 2022, 3 (03)
  • [40] Antiviral treatment for COVID-19: the evidence supporting remdesivir
    Richardson, Charlotte
    Bhagani, Sanjay
    Pollara, Gabriele
    CLINICAL MEDICINE, 2020, 20 (06)
12345